bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2013: M A M F J
2012: D N O S A J J M

  Health Highlights: Jan. 21, 2013

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

Study Will Test Drug for Alzheimer's Prevention

An experimental drug called solanezumab will be used in a large U.S. government-funded study that will assess if it's possible to prevent Alzheimer's disease in seniors at high risk for the brain disorder.

Previous research found that the drug -- which is meant to help clear the amyloid plaques that are a main cause of Alzheimer's -- did not help patients with moderate to severe disease, the Associated Press reported.

However, solanezumab did show some promise in people with milder Alzheimer's and researchers believe it might help this group of patients.

"The hope is we can catch people before they decline," Dr. Reisa Sperling, who is director of the Alzheimer's center at Brigham and Women's Hospital in Boston and will help lead the new study, told the AP.

The clinical trial will include 1,000 people ages 70 to 85 whose brain scans reveal plaques but who do not yet show any signs of dementia. The patients will receive monthly infusions of either solanezumab or a placebo for three years.

The main objective of the study will be to slow the rate of the patients' mental decline. Sperling said the research will be conducted at 50 locations in the U.S. and possibly others in Australia, Europe and Canada, the AP reported.

Solanezumab is an Eli Lilly & Co. drug.

About five million people in the U.S. have Alzheimer's, which is the most common type of dementia. Current medicines can easy symptoms, but there is no known cure.

-----

Global Treaty Seeks to Reduce Mercury Emissions

More than 140 nations on Saturday adopted a legally binding international treaty to reduce emissions of mercury, which poses a number of health risks.

The deal seeks to reduce mercury pollution from utility plants, mining, industrial processes, and a wide range of consumer products. This would be done by setting enforceable limits and by promoting alternatives in which mercury is not used, released or emitted, the Associated Press reported.

Mercury can cause nerve damage, brain and kidney damage, memory loss and language impairment.

The treaty "will help us to protect human health and the environment all over the world," Swiss environment ambassador Franz Perrez told a news conference, the AP reported.

Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=672699

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Mercury
Brain
Dementia
Risk
Alzheimer Disease
Lead
Brain Diseases
Memory Disorders
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact